Skip to main content
OpenTrials
Completed

NCT Number: NCT00957944

Study in Healthy Volunteers to Prove That Two Rotigotine Patches From Different Manufacturing Sites Deliver Equivalent Drug Amount to the Body

The major aim of this study is to investigate and compare the drug amount delivered to the body after sequential application of 2 rotigotine transdermal patches from 2 different manufacturing sites.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Healthy Volunteers

Age range

18 year–55 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 1

Primary location

Neuss, North Rhine-Westphalia, Germany

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • healthy, white, male volunteers between 18 and 55 years of age (inclusive)
  • BMI between 19 and 28 kg/m² (inclusive)

Exclusion criteria

  • previous participation in a clinical study with Rotigotine
  • history or current condition of epilepsy and/or seizures
  • known clinically relevant allergy or known/suspected clinically relevant drug hypersensitivity
  • history of significant skin hypersensitivity to adhesives or other transdermal products or recently unresolved contact dermatitis
  • history or present condition of an atopic or eczematous dermatitis, psoriasis, and/or an active skin disease
  • clinically relevant abnormality in physical examination, ECG, vital signs or safety laboratory examinations
  • positive HIV, hepatitis B or C test or positive alcohol or drug test
  • relevant hepatic or renal dysfunction
  • intake of medication that might interfere with the test drug within 2 weeks prior to dosing
  • thickly hair-covered abdomen resulting in difficulties in finding appropriate patch application sites

Treatment and study plan

rotigotine transdermal patch (Neupro®)

Drug

Rotigotine 4.5 mg/10 cm^2 patch applied for 24 hours

Other names: Neupro®

Primary outcomes

  1. AUC(0-tz) of Unconjugated Rotigotine

    Time frame: Pharmacokinetic samples were taken predose, after 1, 2, 3, 4, 6, 8, 12, 16, 24 (before patch removal), 25, 26, 28, 30, 32, 36, 40 and 48 hours after patch application.

    The AUC(0-tz) is the area under the plasma concentration- time curve from zero up to the last analytically quantifiable concentration.

  2. Cmax of Unconjugated Rotigotine

    Time frame: Pharmacokinetic samples were taken predose, after 1, 2, 3, 4, 6, 8, 12, 16, 24 (before patch removal), 25, 26, 28, 30, 32, 36, 40 and 48 hours after patch application.

    The Cmax is the maximum plasma concentration.

  3. AUC(0-∞) of Unconjugated Rotigotine

    Time frame: Pharmacokinetic samples were taken predose, after 1, 2, 3, 4, 6, 8, 12, 16, 24 (before patch removal), 25, 26, 28, 30, 32, 36, 40 and 48 hours after patch application.

    The AUC(0-∞) is the area under the plasma concentration- time curve from zero up to infinity

Secondary outcomes

  1. AUC(0-tz) Norm (Apparent Dose) of Unconjugated Rotigotine

    Time frame: Pharmacokinetic samples were taken predose, after 1, 2, 3, 4, 6, 8, 12, 16, 24 (before patch removal), 25, 26, 28, 30, 32, 36, 40 and 48 hours after patch application.

    The AUC(0-tz) norm (apparent dose) is the area under the plasma concentration- time curve from zero up to the last analytically quantifiable concentration normalized by apparent dose (mg).

  2. AUC(0-tz) Norm (BW) of Unconjugated Rotigotine

    Time frame: Pharmacokinetic samples were taken predose, after 1, 2, 3, 4, 6, 8, 12, 16, 24 (before patch removal), 25, 26, 28, 30, 32, 36, 40 and 48 hours after patch application.

    The AUC(0-tz) norm (BW) is the area under the plasma concentration- time curve from zero up to the last analytically quantifiable concentration normalized by body weight (kg).

  3. AUC(0-∞) Norm (Apparent Dose)

    Time frame: Pharmacokinetic samples were taken predose, after 1, 2, 3, 4, 6, 8, 12, 16, 24 (before patch removal), 25, 26, 28, 30, 32, 36, 40 and 48 hours after patch application.

    The AUC(0-∞) norm (apparent dose) is the area under the plasma concentration- time curve from zero up to infinity normalized by apparent dose (mg).

  4. AUC(0-∞) Norm (BW)

    Time frame: Pharmacokinetic samples were taken predose, after 1, 2, 3, 4, 6, 8, 12, 16, 24 (before patch removal), 25, 26, 28, 30, 32, 36, 40 and 48 hours after patch application.

    The AUC(0-∞) norm (BW) is the area under the plasma concentration- time curve from zero up to infinity normalized by body weight (kg).

  5. Cmax,Norm (Apparent Dose) of Unconjugated Rotigotine

    Time frame: Pharmacokinetic samples were taken predose, after 1, 2, 3, 4, 6, 8, 12, 16, 24 (before patch removal), 25, 26, 28, 30, 32, 36, 40 and 48 hours after patch application.

    The Cmax,norm (apparent dose) is the maximum plasma concentration normalized by apparent dose(mg).

  6. Cmax,Norm (BW) of Unconjugated Rotigotine

    Time frame: Pharmacokinetic samples were taken predose, after 1, 2, 3, 4, 6, 8, 12, 16, 24 (before patch removal), 25, 26, 28, 30, 32, 36, 40 and 48 hours after patch application.

    The Cmax,norm (BW) is the maximum plasma concentration normalized by body weight(kg).

  7. Tmax of Unconjugated Rotigotine

    Time frame: Pharmacokinetic samples were taken predose, after 1, 2, 3, 4, 6, 8, 12, 16, 24 (before patch removal), 25, 26, 28, 30, 32, 36, 40 and 48 hours after patch application.

    The tmax is the time to reach a maximum plasma concentration after patch application.

  8. MRT of Unconjugated Rotigotine

    Time frame: Pharmacokinetic samples were taken predose, after 1, 2, 3, 4, 6, 8, 12, 16, 24 (before patch removal), 25, 26, 28, 30, 32, 36, 40 and 48 hours after patch application.

    The MRT is the mean residence time.

  9. λz of Unconjugated Rotigotine

    Time frame: Pharmacokinetic samples were taken predose, after 1, 2, 3, 4, 6, 8, 12, 16, 24 (before patch removal), 25, 26, 28, 30, 32, 36, 40 and 48 hours after patch application.

    The λz is the rate constant of elimination.

  10. t1/2 of Unconjugated Rotigotine

    Time frame: Pharmacokinetic samples were taken predose, after 1, 2, 3, 4, 6, 8, 12, 16, 24 (before patch removal), 25, 26, 28, 30, 32, 36, 40 and 48 hours after patch application.

    The t1/2 is the terminal half- life.

  11. CL/f of Unconjugated Rotigotine

    Time frame: Pharmacokinetic samples were taken predose, after 1, 2, 3, 4, 6, 8, 12, 16, 24 (before patch removal), 25, 26, 28, 30, 32, 36, 40 and 48 hours after patch application.

    The CL/f is the apparent total body clearance.

  12. Apparent Dose

    Time frame: 48 hours

    Apparent dose of unconjugated rotigotine in mg. The apparent dose of unconjugated rotigotine was determined from the patches removed on Day 2.

Sponsors and collaborators

Lead sponsor

UCB Pharma

Industry

Registry information

Official study title

Single-site, Open-label, Randomized, Cross-over Trial to Evaluate the Bioequivalence of Single Dose Rotigotine Transdermal Patch (4.5 mg/10 cm^2) From 2 Different Manufacturing Sites.

Important dates

Study start
2009
Primary completion
2009
Study completion
2009
First posted
Aug 13, 2009
Registry last updated
Oct 27, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.